<div id="readability-page-1"><p><span>STAAR Surgical (NASDAQ:STAA - Get Free Report)</span> was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Saturday.</p><div><p><span></span><span>Get <strong>STAAR Surgical</strong> alerts:</span></p></div><ul><li>Top 4 Stocks With Notable Insider Buying</li></ul><p>Other analysts also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a &#34;hold&#34; rating in a report on Thursday. Canaccord Genuity Group boosted their price objective on shares of STAAR Surgical from $27.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Morgan Stanley started coverage on shares of STAAR Surgical in a report on Friday, January 16th. They set an &#34;underweight&#34; rating and a $13.00 price objective on the stock. Piper Sandler boosted their price objective on shares of STAAR Surgical from $16.00 to $33.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday. Finally, Wedbush raised shares of STAAR Surgical from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the stock from $26.00 to $40.00 in a report on Thursday. Three analysts have rated the stock with a Buy rating, six have issued  a Hold rating and two have issued  a Sell rating to the company. According to MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and a consensus target price of $27.81.</p><p><b>Check Out Our Latest Research Report on STAAR Surgical</b></p><h2>STAAR Surgical Stock Up 0.2%</h2><ul><li>Star Surgical Shines as U.S. Outlook Improves for 2024 </li></ul><p>Shares of NASDAQ STAA opened at $32.07 on Friday. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -74.58 and a beta of 1.20. STAAR Surgical has a 52 week low of $15.59 and a 52 week high of $35.87. The firm has a 50-day moving average price of $22.74 and a 200 day moving average price of $22.65. The company has a quick ratio of 3.74, a current ratio of 5.12 and a debt-to-equity ratio of 0.09. </p><p>STAAR Surgical (NASDAQ:STAA - Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.05. The firm had revenue of $93.52 million for the quarter, compared to the consensus estimate of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm's revenue was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.10) earnings per share.  Equities research analysts anticipate that  STAAR Surgical will post -0.03 EPS for the current fiscal year. </p><h2>Insider Transactions at STAAR Surgical</h2><p>In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of the business's stock in a transaction on Friday, March 13th. The stock was bought at an average price of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares in the company, valued at approximately $300,064,699.62. The trade was a 2.00% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 670,213 shares of company stock worth $12,266,249 in the last ninety days. Insiders own  39.90% of the company's stock. </p><h2>Hedge Funds Weigh In On STAAR Surgical</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STAA. Caitong International Asset Management Co. Ltd raised its position in  STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 1,016 shares during the last quarter.  Ascentis Independent Advisors acquired a new position in shares of  STAAR Surgical in the first quarter valued at approximately $77,000.  Tower Research Capital LLC TRC raised its position in shares of  STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 4,673 shares during the last quarter.  Russell Investments Group Ltd. raised its position in shares of  STAAR Surgical by 9,928.9% in the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 4,468 shares during the last quarter.  Finally, Wolverine Asset Management LLC acquired a new position in shares of  STAAR Surgical in the third quarter valued at approximately $199,000. Institutional investors and hedge funds own  96.70% of the company's stock. </p><h2>More STAAR Surgical News</h2><p>Here are the key news stories impacting STAAR Surgical this week:</p><ul>   <li><span>Positive Sentiment: </span>STAAR Surgical beat Q1 earnings and revenue expectations, with the business swinging to a profit and showing strong year-over-year improvement. <i></i><span>Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates</span></li>   <li><span>Positive Sentiment: </span>Wedbush upgraded STAA to <strong>Outperform</strong> and lifted its price target to $40, citing improving prospects tied to a China recovery. <i></i><span>STAAR Surgical was upgraded by Wedbush</span></li>   <li><span>Positive Sentiment: </span>Mizuho also turned more constructive on the stock with a higher price target, reflecting better earnings momentum and outlook expectations. <i></i><span>Mizuho Issues Positive Forecast for STAAR Surgical Stock Price</span></li>   <li><span>Positive Sentiment: </span>Commentary around the earnings call highlighted China strength, cost discipline, and stabilizing inventory as drivers of the turnaround. <i></i><span>Staar Surgical Signals Sharp Turnaround Amid China Strength</span></li>   <li><span>Neutral Sentiment: </span>Wells Fargo raised its price target to $25 but kept an <strong>Equal Weight</strong> rating, signaling some caution despite the recent rally. <i></i><span>STAAR Surgical had its price target raised by Wells Fargo</span></li>   <li><span>Negative Sentiment: </span>Some analysts still see limited visibility into STAAR Surgical’s 2026 outlook, and a new risk disclosure added to uncertainty around future performance and valuation. <i></i><span>Staar Surgical Faces Heightened Uncertainty</span></li> </ul><h2>About STAAR Surgical</h2> (Get Free Report)<p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.</p><h2>See Also</h2><ul><li>Five stocks we like better than STAAR Surgical</li><li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li><li>Datavalut Gains Traction: 5 Reasons to Sell Now</li><li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li><li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in STAAR Surgical Right Now?</h2><p>Before you consider STAAR Surgical, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.</p><p>While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

STAA

<p>Wall Street Zen upgraded STAAR Surgical (NASDAQ:STAA) from a 'hold' to a 'buy' rating. Other analysts have also raised their price targets, with Stifel Nicolaus increasing it from $18 to $31, and Canaccord Genuity from $27 to $32. The stock opened at $32.07, with a market cap of $1.60 billion. Recent earnings showed a revenue increase of 119.6% year-over-year, with EPS of $0.10, surpassing estimates.</p>

Market Beat

STAAR Surgical

iShares US Medical Devices

SPDR S&P Health Equip

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STAAR Surgical (NASDAQ:STAA) Upgraded at Wall Street Zen